Mirum Pharmaceuticals

Mirum

Mirum Pharmaceuticals develops and commercialises therapies for patients with rare cholestatic liver diseases and other debilitating conditions.

Mereo BioPharma

The company develops clinical-stage therapies for patients with rare diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

madrigal-pharma

This biopharmaceutical company develops and manufactures liver-directed therapeutics to treat metabolic dysfunction-associated steatohepatitis for patients with chronic liver diseases.

Cymabay Therapeutics

This biopharmaceutical company develops oral therapies for patients with chronic liver diseases and metabolic disorders including primary biliary cholangitis.

Alnylam Pharmaceuticals

This biopharmaceutical company develops and commercialises RNA interference therapeutics to treat patients with rare, genetic, cardio-metabolic, and infectious diseases.

Northsea Therapeutics

This company develops structurally engineered fatty acid drugs for patients with metabolic, inflammatory, and fibrotic diseases such as rare liver disorders.

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.